As mentioned in the “Patients and Methods” section, we consecutively enrolled a total of 224 patients who received a liver biopsy and evaluated seven genetic polymorphisms associated with the development of NAFLD: PNPLA3 rs738409, transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 [18], 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13) rs72613567, HSD17B13 rs6834314, HSD17B13 rs62305723, membrane-bound O-acyltransferase domain containing 7 (MBOAT7) rs641738 and glucokinase regulatory protein (GCKR) rs1260326 [19,20,21]. The gene discussed is MBOAT7; the disease is metabolic dysfunction-associated steatotic liver disease.